Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Epidemiologi Kesehatan Indonesia Folia Medica Indonesiana
Mokoagow, Md Ikhsan
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Association of Obesity and Negative Acid-Fast Bacilli Finding Among Pulmonary Tuberculosis Patients with Type 2 Diabetes Mellitus Magfira, Nadya; Mokoagow, Md Ikhsan; Kshanti, Ida Ayu; Helda, Helda
Jurnal Epidemiologi Kesehatan Indonesia
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

non-diabetes mellitus population. However, it’s effect on PTB in type 2 diabetes mellitus (T2DM) patient is unclear. The study aims to determine the association between obesity and PTB in patient with T2DM. A cross sectional study was held in in-patient, The Department of Internal Medi cine, Fatmawati General Hospital from January 2015 to December 2017. This study includes patient with T2DM who had been diagnosed with PTB and age > 18 years old. In this study negative Acid-fast-bacilli (AFB) founding defined as patient’s sputum is negative by smear microscopy, while obesity define as body mass index > 24.9 kg/m2. From 363 PTB patient with T2DM, 22.59% were obese. Results showed that prevalence of negative AFB founding in PTB patients with T2DM was 81.82% and it was solely associated with obesity (p:0.002, OR=6.36, 95%CI 1.9-21). Obese patients were likely to have negative AFB founding. It suggested that diagnosing PTB in patient with T2DM and obese can’t be solely based on bacteriological confirmation.
Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia Zihono, Yudivaniel; Yusmaini, Hany; Hasanah, Uswatun; Harfiani, Erna; Mokoagow, Md Ikhsan; Budiman, Dicky
Folia Medica Indonesiana Vol. 59, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlights: 1. As there is a scarcity of publications on the use of metformin for COVID-19 in Indonesia, the findings of this present study may contribute more insight to the existing body of research and provide data specific to the Southeast Asian population. 2. This study revealed a decreased mortality rate associated with metformin use in diabetic patients with mild to moderate COVID-19 infection. 3. This study suggests that diabetic patients may continue metformin treatment during a COVID-19 infection as the medication has sustained therapeutic effects. Abstract COVID-19 patients with comorbidities, such as type 2 diabetes (T2DM), have a higher mortality rate compared to those without any comorbidities. T2DM patients usually receive metformin as their first-line treatment. However, the effectiveness of metformin in reducing mortality rates still requires further analysis. The objective of this study was to analyze the effectiveness of metformin in reducing mortality rates among COVID-19 patients with T2DM. An analytic observational design with a retrospective cohort approach was used in this study. Samples were acquired from hospitalized COVID-19 patients with T2DM medical records at Fatmawati Central General Hospital, Jakarta, Indonesia, throughout 2020–2021. The samples were collected using a purposive sampling technique and analyzed using Chi-square test (p<0.05; RR<1). This study comprised 137 samples, with 56 samples receiving metformin and 81 not receiving metformin. The mortality rate in the sample group that received metformin was lower (19.6%) compared to the group that was not given the medication (38.3%). The Chi-square test results indicated a statistically significant relationship between metformin treatment and a lower mortality rate among COVID-19-contracted individuals with T2DM (p=0.020; RR=0.513). Therefore, this study concludes that the administration of metformin treatment reduces mortality among COVID-19 patients with T2DM.
Co-Authors Budiman, Dicky Erna Harfiani Hany Yusmaini Helda Helda Ida Ayu Kshanti Magfira, Nadya Uswatun Hasanah Zihono, Yudivaniel